Niccolò Siliquini (N Sliquini, N Siliquini)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 15

Top Topics

Atopic Dermatitis

Top Venues

Journal of the European Academy of Dermatology and Venereology : JEADV

Dermatologic therapy

The Journal of dermatological treatment

The British journal of dermatology

This page only lists publications with an associated author ORCID identifier.

Publications

Nicole Macagno, Luca Mastorino, Niccolò Siliquini, Umberto Santaniello, Federica Gelato, Giovanni Cavaliere, Michela Ortoncelli, Simone Ribero, Pietro Quaglino
Safety of dupilumab in patients with cancer. Journal of the European Academy of Dermatology and Venereology : JEADV 38 (9) (2024)
Nicole Macagno, Luca Mastorino, Niccolò Siliquini, Umberto Santaniello, Federica Gelato, Giovanni Cavaliere, Michela Ortoncelli, Simone Ribero, Pietro Quaglino
Safety of dupilumab in patients with cancer. Journal of the European Academy of Dermatology and Venereology : JEADV (2024)
Nadia Sciamarrelli, Niccolò Siliquini, Luca Mastorino, Rebecca Senetta, Paolo Dapavo, Simone Ribero, Pietro Quaglino
Exacerbation of acquired perforating dermatosis following SARS-CoV-2 vaccination. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Nadia Sciamarrelli, Niccolò Siliquini, Luca Mastorino, Rebecca Senetta, Paolo Dapavo, Simone Ribero, Pietro Quaglino
Exacerbation of Acquired Perforating Dermatosis Following SARS-CoV-2 Vaccination. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Luca Mastorino, S Susca, C Cariti, Niccolò Siliquini, A Verrone, E Stroppiana, M Ortoncelli, P Dapavo, Simone Ribero, Pietro Quaglino
Efficacy of anti-IL-23 and anti-IL-17 after adalimumab failure in psoriatic patients. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Luca Mastorino, Gabriele Roccuzzo, Paolo Dapavo, Niccolò Siliquini, Gianluca Avallone, Marco Rubatto, Pietro Quaglino, Simone Ribero
Switching from IL23 inhibitors to IL17 inhibitors: A safe and effective practice? Dermatologic therapy 35 (9) (2022)
Luca Mastorino, Gabriele Roccuzzo, Paolo Dapavo, Niccolò Siliquini, Gianluca Avallone, Marco Rubatto, Martina Merli, Andrea Agostini, Simone Ribero, Pietro Quaglino
Patients with psoriasis resistant to multiple biological therapies: characteristics and definition of a difficult-to-treat population. The British journal of dermatology 187 (2) (2022)
Luca Mastorino, Sara Susca, Matteo Megna, Niccolò Siliquini, Pietro Quaglino, Michela Ortoncelli, Gianluca Avallone, Marco Rubatto, Gabriella Fabbrocini, Paolo Dapavo, Simone Ribero
Risankizumab shows high efficacy and maintenance in improvement of response until week 52. Dermatologic therapy 35 (5) (2022)
Luca Mastorino, Niccolò Siliquini, Gianluca Avallone, Mattia Zenone, Michela Ortoncelli, Pietro Quaglino, Paolo Dapavo, Simone Ribero
Guselkumab shows high efficacy and maintenance in the improvement of response until week 48, a real-life study. Dermatologic therapy 35 (10) (2022)
Niccolò Siliquini, Maria Teresa Giura, R Viola, Simone Ribero, M Panzone, P Dapavo, M T Fierro, M Ortoncelli, Pietro Quaglino
Atopic dermatitis, dupilumab and cancers: a case series. Journal of the European Academy of Dermatology and Venereology : JEADV 35 (10) (2021)
Paolo Dapavo, Niccolò Siliquini, Luca Mastorino, Gianluca Avallone, Martina Merli, Andrea Agostini, Caterina Cariti, Riccardo Viola, Elena Stroppiana, Anna Verrone, Michela Ortoncelli, Pietro Quaglino, Simone Ribero
Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: a retrospective study. The Journal of dermatological treatment (2021)
C Cariti, P Dapavo, L Mastorino, M Ortoncelli, Niccolò Siliquini, M Merli, G Avallone, S Giordano, R Fabrizio, S Susca, A Verrone, E Stroppiana, Pietro Quaglino, Simone Ribero
Comparison of Secukinumab and Ixekizumab in psoriasis: a real-life cohort study on the efficacy and drug survival of 445 patients. Journal of the European Academy of Dermatology and Venereology : JEADV (2021)
Niccolò Siliquini, Riccardo Viola, Maria Teresa Giura, Maria Teresa Fierro, Simone Ribero, Michela Ortoncelli
Case of bladder cancer during Dupilumab therapy: Just an incidental event? Dermatologic therapy 33 (6) (2020)
Alice Ramondetta, M Panzone, P Dapavo, M Ortoncelli, Maria Teresa Giura, M Licciardello, G Rozzo, Niccolò Siliquini, M T Fierro, Simone Ribero
Chilblain acral lesions in the COVID-19 era. Are they marker of infection in asymptomatic patients? Journal of the European Academy of Dermatology and Venereology : JEADV 34 (9) (2020)
Simone Ribero, Maria Teresa Giura, R Viola, A Ramondetta, Niccolò Siliquini, P Cardone, L Tonella, P Quaglino, P Dapavo, M Panzone, M Ortoncelli, M T Fierro
Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in adult cohort: a real-life Italian tertiary centre experience. Journal of the European Academy of Dermatology and Venereology : JEADV 34 (8) (2020)